If ongoing research confirms their efficacy, SGLT2 inhibitors could become a therapeutic option for non-alcoholic fatty liver disease (NAFLD) and its more severe form, non-alcoholic steatohepatitis (NASH). This evidence concerns the gene SLC5A2 and metabolic dysfunction-associated steatotic liver disease.